aTyr Pharma Inc (OQ:LIFE)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 10240 Sorrento Valley Road, Suite 300
SAN DIEGO CA 92121
Tel: N/A
Website: https://www.atyrpharma.com
IR: See website
<
Key People
Sanjay S. Shukla
President, Chief Executive Officer, Director
Jill M. Broadfoot
Chief Financial Officer
Nancy E. Denyes
General Counsel, Corporate Secretary
Business Overview
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).
Financial Overview
For the fiscal year ended 31 December 2023, aTyr Pharma Inc revenues decreased 97% to $353K. Net loss increased 11% to $50.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase of 23% to $2M (expense), Stock-based Compensation in R&D increase of 14% to $600K (expense).
Employees: 56 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $39.26M as of Dec 31, 2023
Annual revenue (TTM): $0.35M as of Dec 31, 2023
EBITDA (TTM): -$54.33M as of Dec 31, 2023
Net annual income (TTM): -$50.39M as of Dec 31, 2023
Free cash flow (TTM): -$37.44M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 67,750,024 as of Mar 13, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.